International Journal of Radiation Oncology*Biology*Physics
Clinical investigationBrainIntensity-modulated radiotherapy in high-grade gliomas: Clinical and dosimetric results
Introduction
The combination of surgery, radiotherapy, and chemotherapy represents the standard approach to the treatment of malignant gliomas. However, survival remains poor. The median survival time with conventional therapy for patients with glioblastoma multiforme is 10–12 months, with a 3-year survival rate of 6–8% (1). The median survival time for patients with anaplastic astrocytoma is 36 months, and the 3-year survival rate is approximately 50%. The pattern of recurrence in high-grade gliomas is almost always local (2). The inability to deliver adequate radiation to the target volume often has been cited as the cause for local failure (3).
Radiation treatment planning for gliomas can be challenging. The goal of treatment planning is to spare the critical structures while delivering the complete prescription dose to the target volume. The tumor often lies in close proximity or surrounds several radiosensitive normal tissues, including the eyes, optic nerves, chiasm, brainstem, and spinal cord. The tolerance of these tissues is less than the desired prescription dose, and the associated morbidity can be severe. Any effort to decrease the treatment toxicity might result in compromised target coverage with conventional therapy, thus increasing the risk of local recurrence.
Intensity-modulated radiotherapy (IMRT) is a more advanced form of three-dimensional conformal radiotherapy (3D-CRT) that relies on advanced accelerator and multileaf collimator technology to deliver nonuniform beam intensities. This approach has been demonstrated to improve tumor coverage while decreasing the dose to critical structures in the head and neck and other sites (4, 5). At present there is very little clinical or dosimetric data regarding the dose distribution and outcomes from IMRT in the treatment of malignant gliomas (6). This retrospective analysis presents the preliminary data on the potential benefits of IMRT in high-grade gliomas.
Section snippets
Methods and materials
Fifty-eight consecutive patients with high-grade gliomas received radiotherapy with IMRT between January 2001 and December 2003 at Memorial Sloan-Kettering Cancer Center (MSKCC). Institutional review board approval was obtained for retrospective review of the data. Patient characteristics are shown in Table 1. Glioblastoma accounted for 70% of the cases. Anaplastic astrocytoma and anaplastic oligodendroglioma histology (pure or mixed) constituted 15% each of the cases. Surgery was limited to
Results
With a median follow-up of 24 months (range, 12–48 months), 49 of the 58 patients (85%) have relapsed. Forty-seven (96%) of the recurrences were local. Of the remaining 2 patients, 1 recurred in a different lobe of the brain outside the radiated region, whereas the other had a leptomeningeal relapse.
Discussion
There has been a dramatic improvement in radiotherapy techniques over the last 2 decades. Improvements in dose distribution and local control have been observed with 3D-CRT as compared with conventional two-dimensional treatment planning for prostate cancer and subsequently for other tumor locations (9, 10). It has also been shown that the morbidity of therapy decreased with the use of 3D-CRT compared with conventional treatment planning (11). Furthermore, IMRT has been shown to improve the
References (18)
- et al.
Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer
Int J Radiat Oncol Biol Phys
(2001) - et al.
Intensity-modulated radiation therapy for pediatric medulloblastomaEarly report on the reduction of ototoxicity
Int J Radiat Oncol Biol Phys
(2002) - et al.
A phase I dose escalating study of intensity modulated radiation therapy (IMRT) for the treatment of glioblastoma multiforme (GBM)
Int J Radiat Oncol Biol Phys
(2002) - et al.
Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy
J Urol
(2003) - et al.
Improved dose distributions for 3D conformal boost treatments in carcinoma of the nasopharynx
Int J Radiat Oncol Biol Phys
(1991) - et al.
Late rectal toxicity after conformal radiotherapy of prostate cancer (I)Multivariate analysis and dose-response
Int J Radiat Oncol Biol Phys
(2000) - et al.
High-dose intensity modulated radiation therapy for prostate cancerEarly toxicity and biochemical outcome in 772 patients
Int J Radiat Oncol Biol Phys
(2002) - et al.
Intensity-modulated radiation therapy for head-and-neck cancerThe UCSF experience focusing on target volume delineation
Int J Radiat Oncol Biol Phys
(2003) - et al.
Intensity-modulated stereotactic radiotherapy vs. stereotactic conformal radiotherapy for the treatment of meningioma located predominantly in the skull base
Int J Radiat Oncol Biol Phys
(2003)
Cited by (129)
Radiation guidelines for gliomas
2022, Cancer/RadiotherapieCitation Excerpt :Intensity-modulated radiotherapy (IMRT) is an option that has not been validated [84]. Its value in terms of survival has not yet been demonstrated [85,86] but it is used in trials to evaluate the protective effect on healthy tissue without necessarily improving local control rates or as an option to increase the dose within the tumour (hypofractionation, concomitant boost) with or without the use of functional imaging (PET, multimodal MRI) to improve local control [9,15,50–54]. Although quality of life studies must be associated with its use [87].
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
2021, Pharmacological ResearchSP1 transcriptionally activates NLRP6 inflammasome and induces immune evasion and radioresistance in glioma cells
2021, International ImmunopharmacologyNovel Magnetic Resonance Imaging and Positron Emission Tomography in the RT Planning and Assessment of Response of Malignant Gliomas
2021, Molecular Imaging: Principles and PracticeIntraoperative radiotherapy for glioblastoma: an international pooled analysis
2020, Radiotherapy and OncologyInfluence of volumetric modulated arc therapy and FET-PET scanning on treatment outcomes for glioblastoma patients
2019, Radiotherapy and Oncology